{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:07:10Z","timestamp":1789229230271,"version":"build-2803163510"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Health and Labor Sciences Research"},{"name":"Ministry of Health, Labor and Welfare (MHLW) of Japan","award":["20316729"],"award-info":[{"award-number":["20316729"]}]},{"name":"Japanese Society for the Promotion of Science (JSPS) KAKENHI","award":["24K11158"],"award-info":[{"award-number":["24K11158"]}]},{"name":"Japanese Society for the Promotion of Science (JSPS) KAKENHI","award":["JP23K15078"],"award-info":[{"award-number":["JP23K15078"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endoscopy is the standard for assessing mucosal activity in ulcerative colitis (UC), but reliable biomarkers are needed. This study evaluated serum amyloid A (SAA) as a potential biomarker by comparing it with established markers in UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively evaluated 182 patients with UC who underwent blood and stool testing within 14\u2009days of colonoscopy at a tertiary care hospital between April 2017 and January 2025. Patients were classified into 4 groups according to the Mayo Endoscopic Subscore (MES). Baseline characteristics and laboratory and endoscopic variables were compared across groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Serum SAA levels demonstrated strong positive correlations with leucine-rich \u03b1-2-glycoprotein (LRG) (r\u2009=\u20090.752) and C-reactive protein (CRP) (r\u2009=\u20090.717). Significant associations were also observed between SAA and MES, Mayo score, partial Mayo score, and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (all P\u2009&amp;lt;\u2009.01). SAA identified active endoscopic inflammation (MES \u2265 2) at a cutoff value of 4.1\u2009mg\/L, with an area under the curve (AUC) of 0.813 (95% CI, 0.731-0.894), sensitivity of 0.804, and specificity of 0.741. In addition, SAA differentiated MES 0 from MES 1 at a cutoff value of 2.6\u2009mg\/L, yielding an AUC of 0.683 (95% CI, 0.470-0.897), sensitivity of 0.706, and specificity of 0.714.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SAA exhibits diagnostic performance comparable to, and in some respects exceeding, that of established inflammatory biomarkers in UC. Importantly, SAA effectively discriminates between MES 0 and MES 1, supporting its potential role as a sensitive marker of mucosal healing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/crocol\/otag097","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:18:57Z","timestamp":1788520737000},"source":"Crossref","is-referenced-by-count":0,"title":["Serum amyloid a as a high-resolution indicator of mucosal healing in ulcerative colitis"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7002-673X","authenticated-orcid":false,"given":"Kotaro","family":"Akita","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine , Sapporo, Hokkaido,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-1048","authenticated-orcid":false,"given":"Yoshihiro","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine , Sapporo, Hokkaido,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2261-3830","authenticated-orcid":false,"given":"Yuta","family":"Shimomori","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine , Sapporo, Hokkaido,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoe","family":"Kazama","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine , Sapporo, Hokkaido,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8788-2522","authenticated-orcid":false,"given":"Masanori","family":"Nojima","sequence":"additional","affiliation":[{"name":"Center for Translational Research, The Institute of Medical Science Hospital, The University of Tokyo , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2848-6586","authenticated-orcid":false,"given":"Hiroshi","family":"Nakase","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University School of Medicine , Sapporo, Hokkaido,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2026091211270350900_otag097-B1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J Gastroenterol"},{"key":"2026091211270350900_otag097-B2","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2026091211270350900_otag097-B3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000485019","article-title":"Endoscopic surveillance in inflammatory bowel disease","volume":"34","author":"Goetz","year":"2018","journal-title":"Visc Med"},{"key":"2026091211270350900_otag097-B4","doi-asserted-by":"publisher","first-page":"462","DOI":"10.20524\/aog.2022.0732","article-title":"How to assess endoscopic disease activity in ulcerative colitis in 2022","volume":"35","author":"Di Ruscio","year":"2022","journal-title":"Ann Gastroenterol"},{"key":"2026091211270350900_otag097-B5","doi-asserted-by":"publisher","first-page":"12431","DOI":"10.1038\/s41598-021-90558-z","article-title":"C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis","volume":"11","author":"Ishida","year":"2021","journal-title":"Sci Rep"},{"key":"2026091211270350900_otag097-B6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/ecco-jcc\/jjw132","article-title":"Leucine-rich alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis","volume":"11","author":"Shinzaki","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026091211270350900_otag097-B7","doi-asserted-by":"publisher","first-page":"11086","DOI":"10.1038\/s41598-021-90441-x","article-title":"Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease","volume":"11","author":"Yasutomi","year":"2021","journal-title":"Sci Rep"},{"key":"2026091211270350900_otag097-B8","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.3390\/jcm10102203","article-title":"Faecal calprotectin in assessment of mucosal healing in adults with inflammatory bowel disease: a meta-analysis","volume":"10","author":"Bromke","year":"2021","journal-title":"J Clin Med"},{"key":"2026091211270350900_otag097-B9","doi-asserted-by":"publisher","first-page":"2098293","DOI":"10.1155\/2017\/2098293","article-title":"Fecal calprotectin: a reliable predictor of mucosal healing after treatment for active ulcerative colitis","volume":"2017","author":"Kristensen","year":"2017","journal-title":"Gastroenterol Res Pract"},{"key":"2026091211270350900_otag097-B10","doi-asserted-by":"publisher","first-page":"809225","DOI":"10.3389\/fphar.2021.809225","article-title":"Research progress on leucine-rich alpha-2 glycoprotein 1: a review","volume":"12","author":"Zou","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026091211270350900_otag097-B11","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1093\/ibd\/izae005","article-title":"Diagnostic performance of a fecal calprotectin assay as a biomarker for Mayo endoscopic subscore in ulcerative colitis: result from a tertiary referral center","volume":"30","author":"Suttichaimongkol","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026091211270350900_otag097-B12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/00042737-200208000-00005","article-title":"Faecal calprotectin: a marker of inflammation throughout the intestinal tract","volume":"14","author":"Summerton","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026091211270350900_otag097-B13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.crohns.2014.06.002","article-title":"The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis","volume":"9","author":"Lasson","year":"2015","journal-title":"J Crohns and Colitis"},{"key":"2026091211270350900_otag097-B14","doi-asserted-by":"publisher","first-page":"631299","DOI":"10.3389\/fimmu.2020.631299","article-title":"Serum amyloid a in inflammatory rheumatic diseases: a compendious review of a renowned biomarker","volume":"11","author":"Hosman","year":"2021","journal-title":"Front Immunol"},{"key":"2026091211270350900_otag097-B15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12876-020-01229-8","article-title":"Serum amyloid a is a better predictive biomarker of mucosal healing than C-reactive protein in ulcerative colitis in clinical remission","volume":"20","author":"Wakai","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"2026091211270350900_otag097-B16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3390\/bioengineering12040413","article-title":"Comparative analysis of deep neural networks for automated ulcerative colitis severity assessment","volume":"12","author":"Vezakis","year":"2025","journal-title":"Bioengineering"},{"key":"2026091211270350900_otag097-B17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2026091211270350900_otag097-B18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1046\/j.1432-1327.1999.00657.x","article-title":"Serum amyloid A, the major vertebrate acute-phase reactant","volume":"265","author":"Uhlar","year":"1999","journal-title":"Eur J Biochem"},{"key":"2026091211270350900_otag097-B19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0167-5699(94)90138-4","article-title":"The major acute phase reactants: C-reactive protein, serum amyloid a protein and fibrinogen","volume":"15","author":"Steel","year":"1994","journal-title":"Immunol Today"},{"key":"2026091211270350900_otag097-B20","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.4049\/jimmunol.1002843","article-title":"Serum amyloid a activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway","volume":"186","author":"Niemi","year":"2011","journal-title":"J Immunol"},{"key":"2026091211270350900_otag097-B21","doi-asserted-by":"publisher","first-page":"e96703","DOI":"10.1371\/journal.pone.0096703","article-title":"Serum amyloid a induces NLRP3-mediated IL-1\u03b2 secretion in neutrophils","volume":"9","author":"Migita","year":"2014","journal-title":"PLoS One"},{"key":"2026091211270350900_otag097-B22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1136\/gut.42.2.214","article-title":"Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease","volume":"42","author":"McAlindon","year":"1998","journal-title":"Gut"},{"key":"2026091211270350900_otag097-B23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/BF01540912","article-title":"Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn\u2019s disease","volume":"16","author":"Reimund","year":"1996","journal-title":"J Clin Immunol"},{"key":"2026091211270350900_otag097-B24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/gut.30.6.835","article-title":"Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis or Crohn\u2019s disease","volume":"30","author":"Mahida","year":"1989","journal-title":"Gut"},{"key":"2026091211270350900_otag097-B25","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1093\/ecco-jcc\/jjab076.195","article-title":"P066 exploration of critical molecules for optimizing treatment by analyzing inflammatory cytokines in the intestinal mucosa of patients with inflammatory bowel disease","volume":"15","author":"Yokoyama","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026091211270350900_otag097-B26","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/ibd\/izae278","article-title":"Mediators of filgotinib treatment effects in ulcerative colitis: Exploring circulating biomarkers in the phase 2b\/3 SELECTION study","volume":"31","author":"Nakase","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026091211270350900_otag097-B27","first-page":"12181204","article-title":"Applying biomarkers in treat-to-target approach for IBD","volume":"16","author":"Lutz","year":"2025","journal-title":"Front Immunol"}],"container-title":["Crohn\u2019s &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag097\/70894377\/otag097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag097\/70894377\/otag097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:27:08Z","timestamp":1789226828000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otag097\/8778559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag097","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"otag097"}}